Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Trans fatty acids

This article was originally published in The Tan Sheet

Executive Summary

Providing a separate line item on food nutrition facts labeling for trans fat information is preferred over combining trans fat levels with saturated fat, FTC's Bureaus of Economics and Consumer Protection say in April 17 comments on FDA's proposed rule. FTC staff also recommend FDA consider a health claim regarding the potential link between trans fatty acids and heart disease to help consumers make more informed choices. Published Nov. 7, the proposed rule would affect products containing .5 g or more trans fat per serving, and would prohibit products with over 4 g saturated and trans fat combined from making positive health claims (1"The Tan Sheet" Nov. 15, 1999, In Brief)

You may also be interested in...



Trans fatty acids

Food marketers would be required to disclose the trans fatty acids content of products in the "Nutrition Facts" panel under an FDA proposed rule expected to be published in the Nov. 17 Federal Register. The levels of trans fat also would be considered when attempting to meet the requirements for claims regarding "low saturated fat" and "reduced saturated fat," as well as "lean," "extra lean" and cholesterol claims. Products containing more than 4 g saturated and trans fat combined per serving additionally would be prohibited from making health claims, such as the approved claim for calcium and osteoporosis. The public comment period on the proposal will run for 90 days

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Topics

UsernamePublicRestriction

Register

PS091220

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel